CVE-2017-18228

CVE-2017-18228 is a medium-severity vulnerability in Bmc Remedy Action Request System with a CVSS 3.x base score of 5.4. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-79.

Key facts

Description

Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys/servlet/AttachServlet request.

Frequently asked questions

What is CVE-2017-18228?
Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys/servlet/AttachServlet request.
How severe is CVE-2017-18228?
CVE-2017-18228 has a CVSS 3.x base score of 5.4, rated medium severity. It is exploitable over network with low attack complexity, requires low privileges and user interaction. Impact on confidentiality is low, integrity low, and availability none.
Is CVE-2017-18228 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (40th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2017-18228?
CVE-2017-18228 affects Bmc Remedy Action Request System. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2017-18228?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
When was CVE-2017-18228 published?
CVE-2017-18228 was published on 2018-03-12 and last updated on 2026-06-17.

References

Affected products (1)

More vulnerabilities in Bmc Remedy Action Request System

All CVEs affecting Bmc Remedy Action Request System →

Other CWE-79 (Cross-site Scripting (XSS)) vulnerabilities

Browse all CWE-79 (Cross-site Scripting (XSS)) vulnerabilities →